Role of the promyelocytic leukaemia protein in cell death regulation

Cell Death and Disease

Volumn 3, Issue 1, 2012, Pages

  Salomoni, P ^a   Dvorkina, M ^a   Michod, D ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

HNF4a; MiR 34a; MiRs 200; Snail; Stemness

Indexed keywords

ATM PROTEIN; DEATH RECEPTOR; FAS LIGAND; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; RETINOIC ACID RECEPTOR ALPHA; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; NUCLEAR PROTEIN; ONCOPROTEIN; PML PROTEIN, HUMAN; RETINOIC ACID; RETINOIC ACID RECEPTOR; TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN;

CELL DEATH; CELL NUCLEUS INCLUSION BODY; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; ENDOPLASMIC RETICULUM; GENE CONTROL; GENE IDENTIFICATION; HUMAN; INFORMATION RETRIEVAL; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN FUNCTION; REVIEW; SOLID TUMOR; ANIMAL; CANCER STEM CELL; CELL CYCLE; CELL DIFFERENTIATION; CELL NUCLEUS; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

GASTROPODA;

ANIMALS; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL NUCLEUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; RECEPTORS, RETINOIC ACID; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSLOCATION, GENETIC; TRETINOIN; TUMOR SUPPRESSOR PROTEINS;

EID: 84856816272     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2011.122     Document Type: Review

References (120)

1. de The H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010; 10: 775-783.
2. Piazza F, Gurrieri C, Pandolfi PP. The theory of APL. Oncogene 2001; 20: 7216-7222. (Pubitemid 33105010)
3. Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell 2002; 108: 165-170. (Pubitemid 34161137)
4. Salomoni P, Ferguson BJ, Wyllie AH, Rich T. New insights into the role of PML in tumour suppression. Cell Res 2008; 18: 622-640. (Pubitemid 351793118)
5. Salomoni P. Stemming out of a new PML era? Cell Death Differ 2009; 16: 1083-1092.
6. Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S et al. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 2000; 5: 811-820.
7. Rego EM, Wang ZG, Peruzzi D, He LZ, Cordon-Cardo C, Pandolfi PP. Role of promyelocytic leukemia (PML) protein in tumor suppression. J Exp Med 2001; 193: 521-529. (Pubitemid 32524482)
8. Bellodi C, Kindle K, Bernassola F, Dinsdale D, Cossarizza A, Melino G et al. Cytoplasmic function of mutant promyelocytic leukemia (PML) and PML-retinoic acid receptor-alpha. J Biol Chem 2006; 281: 14465-14473. (Pubitemid 43848377)
9. Gurrieri C, Nafa K, Merghoub T, Bernardi R, Capodieci P, Biondi A et al. Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood 2004; 103: 2358-2362. (Pubitemid 38326258)
10. Kurahashi S, Hayakawa F, Miyata Y, Yasuda T, Minami Y, Tsuzuki S et al. PAX5-PML acts as a dual dominant-negative form of both PAX5 and PML. Oncogene 2011; 30: 1822-1830.
11. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ et al. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 2004; 96: 269-279. (Pubitemid 38256272)
12. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008; 453: 1072-1078. (Pubitemid 351871736)
13. Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D et al. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009; 457: 51-56.
14. Gambacorta M, Flenghi L, Fagioli M, Pileri S, Leoncini L, Bigerna B et al. Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. Am J Pathol 1996; 149: 2023-2035. (Pubitemid 26415220)
15. Lee HE, Jee CD, Kim MA, Lee HS, Lee YM, Lee BL et al. Loss of promyelocytic leukemia protein in human gastric cancers. Cancer Lett 2007; 247: 103-109. (Pubitemid 44959417)
16. Zhang P, Chin W, Chow LT, Chan AS, Yim AP, Leung SF et al. Lack of expression for the suppressor PML in human small cell lung carcinoma. Int J Cancer 2000; 85: 599-605. (Pubitemid 30080469)
17. Koken MH, Linares-Cruz G, Quignon F, Viron A, Chelbi-Alix MK, Sobczak-Thepot J et al. The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 1995; 10: 1315-1324.
18. Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B et al. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 2006; 126: 269-283. (Pubitemid 44092959)
19. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L et al. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 2008; 10: 547-555. (Pubitemid 351627374)
20. Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG et al. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat Cell Biol 2008; 10: 538-546. (Pubitemid 351627373)
21. Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S et al. PML/ RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 2010; 18: 88-98.
22. Condemine W, Takahashi Y, Zhu J, Puvion-Dutilleul F, Guegan S, Janin A et al. Characterization of endogenous human promyelocytic leukemia isoforms. Cancer Res 2006; 66: 6192-6198.
23. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004; 23: 2950-2966. (Pubitemid 38638855)
24. Fas SC, Fritzsching B, Suri-Payer E, Krammer PH. Death receptor signaling and its function in the immune system. Curr Dir Autoimmun 2006; 9: 1-17.
25. Fulda S, Debatin KM. Signaling through death receptors in cancer therapy. Curr Opin Pharmacol 2004; 4: 327-332. (Pubitemid 38987057)
26. Guardiola-Serrano F, Rossin A, Cahuzac N, Luckerath K, Melzer I, Mailfert S et al. Palmitoylation of human FasL modulates its cell death-inducing function. Cell Death Disease 2010; 1: e88.
27. Cheng JP, Betin VM, Weir H, Shelmani GM, Moss DK, Lane JD. Caspase cleavage of the Golgi stacking factor GRASP65 is required for Fas/CD95-mediated apoptosis. Cell Death Disease 2010; 1: e82.
28. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R et al. PML is essential for multiple apoptotic pathways. Nat Genet 1998; 20: 266-272. (Pubitemid 28507671)
29. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H. PML induces a novel caspase-independent death process. Nat Genet 1998; 20: 259-265. (Pubitemid 28507670)
30. Crowder C, Dahle O, Davis RE, Gabrielsen OS, Rudikoff S. PML mediates IFNalpha- induced apoptosis in myeloma by regulating TRAIL induction. Blood 2005; 105: 1280-1287. (Pubitemid 40170904)
31. Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. Immunology 2009; 127: 145-154.
32. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008; 7: 1001-1012.
33. Schneider-Jakob S, Corazza N, Badmann A, Sidler D, Stuber-Roos R, Keogh A et al. Synergistic induction of cell death in liver tumor cells by TRAIL and chemotherapeutic drugs via the BH3-only proteins Bim and Bid. Cell Death Disease 2010; 1: e86.
34. Reis CR, van der Sloot AM, Natoni A, Szegezdi E, Setroikromo R, Meijer M et al. Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Disease 2010; 1: e83.
35. Schneider B, Munkel S, Krippner-Heidenreich A, Grunwald I, Wels WS, Wajant H et al. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Disease 2010; 1: e68.
36. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DB et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005; 12: 773-782. (Pubitemid 40945984)
37. Harper N, MacFarlane M. Recombinant TRAIL and TRAIL receptor analysis. Methods Enzymol 2008; 446: 293-313.
38. Meley D, Spiller DG, White MR, McDowell H, Pizer B, See V. p53-mediated delayed NFkappaB activity enhances etoposide-induced cell death in medulloblastoma. Cell Death Disease 2010; 1: e41.
39. Chipuk JE, Green DR. Dissecting p53-dependent apoptosis. Cell Death Differ 2006; 13: 994-1002.
40. Fricker M, O'Prey J, Tolkovsky AM, Ryan KM. Phosphorylation of Puma modulates its apoptotic function by regulating protein stability. Cell Death Disease 2010; 1: e59.
41. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 2004; 6: 665-672. (Pubitemid 38960925)
42. Kurki S, Latonen L, Laiho M. Cellular stress and DNA damage invoke temporally distinct Mdm2, p53 and PML complexes and damage-specific nuclear relocalization. J Cell Sci 2003; 116: 3917-3925. (Pubitemid 37279307)
43. Louria-Hayon I, Grossman T, Sionov RV, Alsheich O, Pandolfi PP, Haupt Y. The promyelocytic leukemia protein protects p53 from Mdm2-mediated inhibition and degradation. J Biol Chem 2003; 278: 33134-33141. (Pubitemid 37055760)
44. Wei X, Yu ZK, Ramalingam A, Grossman SR, Yu JH, Bloch DB et al. Physical and functional interactions between PML and MDM2. J Biol Chem 2003; 278: 29288-29297. (Pubitemid 36935845)
45. Zhu H, Wu L, Maki CG. MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53. J Biol Chem 2003; 278: 49286-49292.
46. Khelifi AF, D'Alcontres MS, Salomoni P. Daxx is required for stress-induced cell death and JNK activation. Cell Death Differ 2005; 12: 724-733. (Pubitemid 40945980)
47. Salomoni P, Khelifi AF. Daxx: death or survival protein? Trends Cell Biol 2006; 16: 97-104. (Pubitemid 43247405)
48. Song MS, Song SJ, Kim SY, Oh HJ, Lim DS. The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. EMBO J 2008; 27: 1863-1874.
49. Tang J, Qu LK, Zhang J, Wang W, Michaelson JS, Degenhardt YY et al. Critical role for Daxx in regulating Mdm2. Nat Cell Biol 2006; 8: 855-862. (Pubitemid 44151589)
50. Pearson M, Carbone R, Sebastiani C, Cioce M, Fagioli M, Saito S et al. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature 2000; 406: 207-210. (Pubitemid 30469006)
51. Hofmann TG, Will H. Body language: the function of PML nuclear bodies in apoptosis regulation. Cell Death Differ 2003; 10: 1290-1299. (Pubitemid 37536734)
52. Moller A, Sirma H, Hofmann TG, Rueffer S, Klimczak E, DrogeWet al. PML is required for homeodomain-interacting protein kinase 2 (HIPK2)-mediated p53 phosphorylation and cell cycle arrest but is dispensable for the formation of HIPK domains. Cancer Res 2003; 63: 4310-4314. (Pubitemid 36950995)
53. Sung KS, Lee YA, Kim ET, Lee SR, Ahn JH, Choi CY. Role of the SUMO-interacting motif in HIPK2 targeting to the PML nuclear bodies and regulation of p53. Exp Cell Res 2011; 317: 1060-1070.
54. Bellodi C, Kindle K, Bernassola F, Cossarizza A, Dinsdale D, Melino G et al. A cytoplasmic PML mutant inhibits p53 function. Cell Cycle 2006; 5: 2688-2692. (Pubitemid 44785813)
55. Yang S, Kuo C, Bisi JE, Kim MK. PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2. Nat Cell Biol 2002; 4: 865-870. (Pubitemid 35331361)
56. Meltser V, Ben-Yehoyada M, Reuven N, Shaul Y. c-Abl downregulates the slow phase of double-strand break repair. Cell Death Disease 2010; 1: e20.
57. Cummins NW, Badley AD. Mechanisms of HIV-associated lymphocyte apoptosis: 2010. Cell Death Disease 2010; 1: e99.
58. Perfettini JL, Nardacci R, Seror C, Bourouba M, Subra F, Gros L et al. The tumor suppressor protein PML controls apoptosis induced by the HIV-1 envelope. Cell Death Differ 2009; 16: 298-311.
59. Perfettini JL, Nardacci R, Seror C, Raza SQ, Sepe S, Saidi H et al. 53BP1 represses mitotic catastrophe in syncytia elicited by the HIV-1 envelope. Cell Death Differ 2010; 17: 811-820.
60. Agostini M, Tucci P, Chen H, Knight RA, Bano D, Nicotera P et al. p73 regulates maintenance of neural stem cell. Biochem Biophys Res Commun 2010; 403: 13-17.
61. Bernassola F, Salomoni P, Oberst A, Di Como CJ, Pagano M, Melino G et al. Ubiquitin-dependent degradation of p73 is inhibited by PML. J Exp Med 2004; 199: 1545-1557. (Pubitemid 38780409)
62. Dotsch V, Bernassola F, Coutandin D, Candi E, Melino G. p63 and p73, the ancestors of p53. Cold Spring Harb Perspect Biol 2010; 2: a004887.
63. Gonzalez-Cano L, Herreros-Villanueva M, Fernandez-Alonso R, Ayuso-Sacido A, Meyer G, Garcia-Verdugo JM et al. p73 deficiency results in impaired self renewal and premature neuronal differentiation of mouse neural progenitors independently of p53. Cell Death Disease 2010; 1: e109.
64. Killick R, Niklison-Chirou M, Tomasini R, Bano D, Rufini A, Grespi F et al. p73: a multifunctional protein in neurobiology. Mol Neurobiol 2011; 43: 139-146.
65. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV et al. p73 in cancer. Genes Cancer 2011; 2: 491-502.
66. Tomasini R, Mak TW, Melino G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol 2008; 18: 244-252.
67. Tomlinson V, Gudmundsdottir K, Luong P, Leung KY, Knebel A, Basu S. JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis. Cell Death Disease 2010; 1: e29.
68. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell 2005; 18: 447-459. (Pubitemid 40704759)
69. Downward J, Basu S. YAP and p73: a complex affair. Mol Cell 2008; 32: 749-750.
70. Lapi E, Di Agostino S, Donzelli S, Gal H, Domany E, Rechavi G et al. PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell 2008; 32: 803-814.
71. Klanrit P, Taebunpakul P, Flinterman MB, Odell EW, Riaz MA, Melino G et al. PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers. Oncogene 2009; 28: 3499-3512.
72. Mainardi S, Pelosi A, Palescandolo E, Riccioni R, Fontemaggi G, Diverio D et al. deltaNp73 is a transcriptional target of the PML/RARalpha oncogene in myeloid differentiation. Cell Death Differ 2007; 14: 1968-1971. (Pubitemid 350011672)
73. Barton CE, Johnson KN, Mays DM, Boehnke K, Shyr Y, Boukamp P et al. Novel p63 target genes involved in paracrine signaling and keratinocyte differentiation. Cell Death Disease 2010; 1: e74.
74. Yuan M, Luong P, Hudson C, Gudmundsdottir K, Basu S. c-Abl phosphorylation of DeltaNp63alpha is critical for cell viability. Cell Death Disease 2010; 1: e16.
75. Melino G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ 2011; 18: 1487-1499.
76. Shalom-Feuerstein R, Lena AM, Zhou H, De La Forest Divonne S, Van Bokhoven H, Candi E et al. DeltaNp63 is an ectodermal gatekeeper of epidermal morphogenesis. Cell Death Differ 2011; 18: 887-896.
77. Vanbokhoven H, Melino G, Candi E, Declercq W. p63, a story of mice and men. J Invest Dermatol 2011; 131: 1196-1207.
78. Aylon Y, Oren M. New plays in the p53 theater. Curr Opin Genet Dev 2011; 21: 86-92.
79. Mitchell G, Fillinger J, Sittadjody S, Avila J, Burd R, Limesand K. IGF1 activates cell cycle arrest following irradiation by reducing binding of DeltaNp63 to the p21 promoter. Cell Death Disease 2010; 2010: e50.
80. Straub WE, Weber TA, Schafer B, Candi E, Durst F, Ou HD et al. The C-terminus of p63 contains multiple regulatory elements with different functions. Cell Death Disease 2010; 1: e5.
81. Bernassola F, Oberst A, Melino G, Pandolfi PP. The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63. Oncogene 2005; 24: 6982-6986. (Pubitemid 41509421)
82. Salomoni P, Bernardi R, Bergmann S, Changou A, Tuttle S, Pandolfi PP. The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage. Blood 2005; 105: 3686-3690. (Pubitemid 40628217)
83. Lam D, Shah S, de Castro IP, Loh SH, Martins LM. Drosophila happyhour modulates JNK-dependent apoptosis. Cell Death Disease 2010; 1: e66.
84. Brandt B, Abou-Eladab EF, Tiedge M, Walzel H. Role of the JNK/c-Jun/AP-1 signaling pathway in galectin-1-induced T-cell death. Cell Death Disease 2010; 1: e23.
85. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27: 6245-6251.
86. Ito K, Bernardi R, Pandolfi PP. A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell. Curr Opin Genet Dev 2009; 19: 51-59.
87. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J et al. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 2008; 455: 813-817.
88. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007; 128: 141-156. (Pubitemid 46048885)
89. Regad T, Bellodi C, Nicotera P, Salomoni P. The tumor suppressor Pml regulates cell fate in the developing neocortex. Nat Neurosci 2009; 12: 132-140.
90. Blagosklonny MV. Linking calorie restriction to longevity through sirtuins and autophagy: any role for TOR. Cell Death Disease 2010; 1: e12.
91. Chan EY, Longatti A, McKnight NC, Tooze SA. Kinase-inactivated ULK proteins inhibit autophagy via their conserved C-terminal domains using an Atg13-independent mechanism. Mol Cell Biol 2009; 29: 157-171.
92. Deng L, Feng J, Broaddus RR. The novel estrogen-induced gene EIG121 regulates autophagy and promotes cell survival under stress. Cell Death Disease 2010; 1: e32.
93. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ 2009; 16: 966-975.
94. Grander D, Kharaziha P, Laane E, Pokrovskaja K, Panaretakis T. Autophagy as the main means of cytotoxicity by glucocorticoids in hematological malignancies. Autophagy 2009; 5: 1198-1200.
95. Heidari N, Hicks MA, Harada H. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Disease 2010; 1: e76.
96. Laane E, Tamm KP, Buentke E, Ito K, Kharaziha P, Oscarsson J et al. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ 2009; 16: 1018-1029.
97. Li Q, Li H, Roughton K, Wang X, Kroemer G, Blomgren K et al. Lithium reduces apoptosis and autophagy after neonatal hypoxia-ischemia. Cell Death Disease 2010; 1: e56.
98. Liang C. Negative regulation of autophagy. Cell Death Differ 2010; 17: 1807-1815.
99. Maiuri MC, Tasdemir E, Criollo A, Morselli E, Vicencio JM, Carnuccio R et al. Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ 2009; 16: 87-93.
100. Marino G, Madeo F, Kroemer G. Autophagy for tissue homeostasis and neuroprotection. Curr Opin Cell Biol 2011; 23: 198-206.
101. McCoy F, Hurwitz J, McTavish N, Paul I, Barnes C, O'Hagan B et al. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death Disease 2010; 1: e108.
102. Morselli E, Maiuri MC, Markaki M, Megalou E, Pasparaki A, Palikaras K et al. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death Disease 2010; 1: e10.
103. Silver N, Proctor GB, Arno M, Carpenter GH. Activation of mTOR coincides with autophagy during ligation-induced atrophy in the rat submandibular gland. Cell Death Disease 2010; 1: e14.
104. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700. (Pubitemid 36724933)
105. Sayeed A, Meng Z, Luciani G, Chen LC, Bennington JL, Dairkee SH. Negative regulation of UCP2 by TGFbeta signaling characterizes low and intermediate-grade primary breast cancer. Cell Death Disease 2010; 1: e53.
106. Lin HK, Bergmann S, Pandolfi PP. Cytoplasmic PML function in TGF-beta signalling. Nature 2004; 431: 205-211. (Pubitemid 39243475)
107. Seo SR, Ferrand N, Faresse N, Prunier C, Abecassis L, Pessah M et al. Nuclear retention of the tumor suppressor cPML by the homeodomain protein TGIF restricts TGF-beta signaling. Mol Cell 2006; 23: 547-559. (Pubitemid 44226449)
108. Faresse N, Colland F, Ferrand N, Prunier C, Bourgeade MF, Atfi A. Identification of PCTA, a TGIF antagonist that promotes PML function in TGF-beta signalling. EMBO J 2008; 27: 1804-1815. (Pubitemid 351960206)
109. Pan D, Zhu Q, Luo K. SnoN functions as a tumour suppressor by inducing premature senescence. EMBO J 2009; 28: 3500-3513.
110. Giorgi C, Ito K, Lin HK, Santangelo C, Wieckowski MR, Lebiedzinska M et al. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. Science 2010; 330: 1247-1251.
111. Pinton P, Giorgi C, Pandolfi PP. The role of PML in the control of apoptotic cell fate: a new key player at ER-mitochondria sites. Cell Death Differ 2011; 18: 1450-1456.
112. Ruiz A, Matute C, Alberdi E. Intracellular Ca2+ release through ryanodine receptors contributes to AMPA receptor-mediated mitochondrial dysfunction and ER stress in oligodendrocytes. Cell Death Disease 2010; 1: e54.
113. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-1130.
114. Tomiyama A, Tachibana K, Suzuki K, Seino S, Sunayama J, Matsuda KI et al. MEK-ERKdependent multiple caspase activation by mitochondrial proapoptotic Bcl-2 family proteins is essential for heavy ion irradiation-induced glioma cell death. Cell Death Disease 2010; 1: e60.
115. Wabnitz GH, Goursot C, Jahraus B, Kirchgessner H, Hellwig A, Klemke M et al. Mitochondrial translocation of oxidized cofilin induces caspase-independent necrotic-like programmed cell death of T cells. Cell Death Disease 2010; 1: e58.
116. Flanagan L, Sebastia J, Tuffy LP, Spring A, Lichawska A, Devocelle M et al. XIAP impairs Smac release from the mitochondria during apoptosis. Cell Death Disease 2010; 1: e49.
117. Karlberg M, Ekoff M, Labi V, Strasser A, Huang D, Nilsson G. Pro-apoptotic Bax is the major and Bak an auxiliary effector in cytokine deprivation-induced mast cell apoptosis. Cell Death Disease 2010; 1: e43.
118. Esposti MD. Bcl-2 antagonists and cancer: from the clinic, back to the bench. Cell Death Disease 2010; 1: e37.
119. Li W, Ferguson BJ, Khaled WT, Tevendale M, Stingl J, Poli V et al. PML depletion disrupts normal mammary gland development and skews the composition of the mammary luminal cell progenitor pool. Proc Natl Acad Sci USA 2009; 106: 4725-4730.
120. Li W, Rich T, Watson CJ. PML: a tumor suppressor that regulates cell fate in mammary gland. Cell Cycle 2009; 8: 2711-2717.